Human chorionic gonadotropin or HCG hormone is produced during pregnancy in women. It supports the normal development of an egg in a woman's ovary, and the egg is released from the ovary during ovulation. HCG hormone is also used medically to stimulate ovulation and pregnancy in infertile women. The use of HCG hormone encourages the healthy development of the early stages of pregnancy.

The Human Chorionic Gonadotropin (HCG) Market is estimated to be valued at US$ 710.88 Mn or Million in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The global HCG market is mainly driven by rising rates of infertility worldwide. In 2020, infertility was estimated to affect around 186 million people globally. Male infertility contributed to around 20-30% of infertility cases and female infertility contributed to 40-55% of cases. The remaining cases were due to combined problems or unknown causes. The rising infertility levels have led to increasing adoption of assisted reproductive technologies (ART) like HCG treatment. Besides this, increasing awareness about infertility treatment options and growing acceptability of HCG hormone for fertility treatment are fueling the growth of the human chorionic gonadotropin market. However, side effects associated with HCG therapy and availability of alternative therapies may hamper market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The Human Chorionic Gonadotropin (HCG) market requires high capital investment and has the presence of well-established players. This makes the threat of new entrants low.

Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative products. However, the established therapies offer value to the patients.

Bargaining power of suppliers: A few major suppliers dominate the raw material supply chain. This gives them moderate bargaining power.

Threat of new substitutes: The Threat from substitutes is moderate as alternate established therapies offer comparable effectiveness.

Competitive rivalry: The competition is high among existing players.

SWOT Analysis

Strength: Wide application areas and proven benefits of HCG Drive demand. Established distribution channels of major players.

Weakness: Strict regulations and compliance requirements add production costs. Short shelf life is a concern.

Opportunity: Increasing fertility disorders prevalence provides untapped growth potential regions. Novel drug delivery methods can boost customer acceptance.

Threats: Price erosion due to patent expiries and entry of biosimilars. Stringent manufacturing practices up costs.

Key Takeaways

The global Human Chorionic Gonadotropin (HCG) market is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing prevalence of fertility-related issues. Advancements in assisted reproductive technologies and rising disposable income also support the market expansion.

Regionally, North America dominated the HCG market in 2023 with over 30% revenue share owing to well-developed healthcare infrastructure and growing healthcare spending. Asia Pacific is anticipated to exhibit fastest growth during 2023-2030 induced by surging medical tourism, rising focus on infertility treatments, and growing generic drugs market in India and China.

Key players operating in the Human Chorionic Gonadotropin market are Merck Co., Inc., Ferring B.V.,Fresenius SE Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.